Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Dissecting mechanisms of mammalian gene regulation by the essential histone acetyltransferases p300 and CBP

FY 2020-21

Summary
Every cell in a human body has the same DNA sequence. However, different segments of DNA, called genes, are read out in each distinct cell type to produce the specific set of proteins needed for cellular function. As such, activating the wrong gene at the wrong time can lead to developmental defects and disease, and many human diseases stem from mutations in regulators of gene activity. Two such regulators are p300 and CBP, which have largely redundant functions and for simplicity will be referred to as p300. p300 stimulates gene activity by chemically modifying proteins in an enzymatic reaction called acetylation. Acetylation alters protein charge, affecting binding partners and enzymatic activities of numerous factors, with pervasive effects on gene activity. Accordingly, p300 frequently works together with other regulatory factors and this cooperation is crucial for gene activation. Aberrant levels or activity of p300 and collaborating factors are implicated in numerous human diseases, including Rubinstein-Taybi syndrome, diabetes, and multiple types of cancer. However, accurately targeting p300 and its co-regulators in disease is challenging because we don't fully understand how these factors work, or work together, to control gene expression. To address this important question, I have used powerful small molecule inhibitors and genomic methods to define genes at which p300 directly stimulates activity at particular steps in the transcription process. Further, this work has revealed distinct sets of genes where p300 collaborates with other factors, providing opportunities to understand co-regulation. Here, I propose to leverage this information to test specific models for p300 activity in gene control. These experiments are anticipated to clarify the basis for gene dysregulation in cells with mutations or perturbations in p300 and suggest new therapeutic avenues to target this factor in disease.
Program
Banting Postdoctoral Fellowship Program
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
436202
Name
Martin Benjamin J
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Dissecting mechanisms of mammalian gene regulation by the essential histone acetyltransferases p300 and CBP
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Brg1; Cbp; Chromatin; Chromatin Remodeling; Gene Activation; Histone Acetylation; P300; Promoter-Proximal Pausing; Rnapii; Transcription
Abstract
Every cell in a human body has the same DNA sequence. However, different segments of DNA, called genes, are read out in each distinct cell type to produce the specific set of proteins needed for cellular function. As such, activating the wrong gene at the wrong time can lead to developmental defects and disease, and many human diseases stem from mutations in regulators of gene activity. Two such regulators are p300 and CBP, which have largely redundant functions and for simplicity will be referred to as p300. p300 stimulates gene activity by chemically modifying proteins in an enzymatic reaction called acetylation. Acetylation alters protein charge, affecting binding partners and enzymatic activities of numerous factors, with pervasive effects on gene activity. Accordingly, p300 frequently works together with other regulatory factors and this cooperation is crucial for gene activation. Aberrant levels or activity of p300 and collaborating factors are implicated in numerous human diseases, including Rubinstein-Taybi syndrome, diabetes, and multiple types of cancer. However, accurately targeting p300 and its co-regulators in disease is challenging because we don't fully understand how these factors work, or work together, to control gene expression. To address this important question, I have used powerful small molecule inhibitors and genomic methods to define genes at which p300 directly stimulates activity at particular steps in the transcription process. Further, this work has revealed distinct sets of genes where p300 collaborates with other factors, providing opportunities to understand co-regulation. Here, I propose to leverage this information to test specific models for p300 activity in gene control. These experiments are anticipated to clarify the basis for gene dysregulation in cells with mutations or perturbations in p300 and suggest new therapeutic avenues to target this factor in disease.
Competitiondate
202010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Martin, Benjamin J
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~
Direct Payment - $140,000 Grant (2020-21) | Canada Spends